Jenny van Asbeck – van der Wijst

Company: Mercurna

Job title: Chief Executive Officer

Seminars:

CEO & Global Leaders Think Tank: Unlocking the Next Frontiers of mRNA-Based Vaccines & Therapeutics to Ensure Better Drugs Reach Patients Faster 8:25 am

What are the future opportunities for the mRNA field towards best-in-class drugs into 2025? What are the biggest challenges you face on a day-to-day basis from asset, deals to risk-management and clinical strategy? What can biotechs get most out of an investment to extend cash-flow and nuances of striking a deal for a new pipeline?Read more

day: Day One

De-LIVER – Solving Extra-Hepatic Targeting Bottlenecks With Delivery to Combat Rare Diseases 10:31 am

Recent advances in mRNA technology and its delivery have enabled mRNA-based therapeutics to enter a new era in medicine with unlimited potential. The rapid, potent, and transient nature of mRNA-encoded proteins, without the need to enter the nucleus or the risk of genomic integration, makes them desirable tools for treatment of a range of diseases.…Read more

day: mRNA Technology & Innovation Day